On July 31, Merck announced that the FDA approved Keytruda monotherapy for patients with recurrent locally advanced or metastatic esophageal squamous cell carcinoma who had previously received at least one line of systemic PD-L1 expression (CPS ≥ 10). This approval is based primarily on data from two studies. One… Continue Reading Keytruda new indications approved, the first esophageal cancer PD-1 therapy
The data displayed by Mercury’s I-O star Keytruda on the ASCO 2018 is amazing, and almost everyone believes that Keytruda has no doubt seized the throne of lung immunotherapy. However, competitors do not seem to agree with this. In their view, the difference between their drug and Keytruda is very… Continue Reading What is the difference between the PD-1/PD-L1 drugs in Merck, BMS, and Roche?
MSD announced on May 23 that a key Phase III study of Keytruda (pembrolizumab) combined with chemotherapy (carboplatin + paclitaxel or naproxen + paclitaxel) for the first-line treatment of metastatic squamous NSCLC achieved overall survival (OS) and progression-free survival ( The two primary endpoints of PFS). The results of an… Continue Reading Keytruda first-line treatment of squamous NSCLC achieves double primary endpoint
“God’s medicine” is usually the reputation of everyone for a drug, such as the cure for hepatitis C sofebuvir, so that President Carter’s brain melanoma disappeared mysteriously PD-1 monoclonal antibody Keytruda; of course, there are those in a large number of clinical trials It has been proved that the indications… Continue Reading What kind of medicine is “God medicine”?